A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
Clinical trial NCT05369403 · COMPLETED
Trial details
- NCT number
- NCT05369403
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-19
- Primary completion
- 2024-01-11
- Enrollment
- 86
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.